Vita Life Sciences Limited Overview
Vita Life Sciences is a small-capitalisation, debt-free Australian consumer-health company that develops, formulates, packages, markets and distributes vitamins, minerals, herbal and nutritional supplements (VMS) and selected over-the-counter (OTC) medicines across Australia and Southeast Asia. It owns three brands — Herbs of Gold (Australian practitioner-style herbal and nutritional range sold through health food stores and pharmacies), VitaHealth (a Singapore-origin heritage brand launched in 1973 and the group's largest earner in Malaysia and Singapore) and VitaScience — with roughly 350 registered products. Unlike scale players such as Swisse or Blackmores, VLS competes through specialist channels, formulation credibility and localised regulatory know-how. Its economic engine is now Malaysia/Singapore, which overtook Australia in FY2025, while China and Vietnam are treated as sub-scale "investment" markets. The company combines record revenue (A$93.3m, FY2025), gross margins above 60%, a 75% dividend payout policy, a 16-year unbroken dividend record and an active on-market buy-back.
Company's own description (FY2025 Annual Report)
The FY2025 Annual Report describes Vita Life Sciences as a multinational healthcare company involved in the formulating, packaging, sale and distribution of vitamins and supplements, represented by two major brands of high-quality supplements throughout the Asia-Pacific region — Vita Health and Herbs of Gold — with VitaScience named as a third brand in the Chairman's Letter. The company states a commitment to the health and well-being of customers, socially responsible conduct, a rewarding working environment for employees and competitive shareholder returns. Its stated strategy is to establish a sustainable platform for revenue growth through expanding operations into new markets within Asia, under the philosophy of "thinking internationally, but acting locally". The Half Year Presentation (August 2026) adds that the core business is the development and distribution of OTC medicines, complementary and alternative medicines, dietary supplements and health foods, formulated by in-house naturopaths, nutritionists, biotechnologists and pharmacists.
Business model and revenue model
| Revenue model element | Disclosure / assessment |
|---|---|
| Product sales (branded VMS / OTC) | ~100% of revenue (FY2025: A$93.27m) |
| Services | Nil disclosed |
| Subscription / recurring contracts | Nil disclosed (repeat purchase is behavioural, not contractual) |
| Licensing / royalties | Nil disclosed. IP is held in Singapore (VitaHealth IP Pte Ltd) for internal use |
| Finance income | A$0.99m interest on cash deposits (FY2025), reported below EBIT |
The group reports a single business — the development and sale of complementary medicines including VMS — organised into geographically managed operating segments. Revenue is almost entirely product revenue from the sale of branded goods ("sale of goods" was the only revenue line in FY2025: A$93.27m). There is no material service, subscription or licensing revenue disclosed. Revenue is recognised at the point of delivery, and is constrained for a contractual right of return granted to retail customers up to product expiry; this gives rise to a "contract return liability" of A$5.70m at 31 December 2025 (A$4.81m at 31 December 2024), a meaningful 6.1% of FY2025 revenue.
Value-chain position
VLS sits in the brand-owner / formulator / marketer layer of the VMS value chain. It controls formulation, regulatory registration (product registration costs: A$0.59m in FY2025), packaging, brand marketing, sales and distribution. Inventories include raw materials (A$5.08m at 31 December 2025) and finished goods (A$11.22m), and the inventory policy references "direct materials and labour and a proportion of manufacturing overheads", indicating some in-house conversion or packaging capability. However, the location and scale of any owned manufacturing is not publicly disclosed; the bulk of PP&E (A$10.3m of A$12.5m) sits in the Malaysia & Singapore segment, including owned land and buildings of A$9.0m. Retail access is through third parties — independent health food stores, pharmacy groups and chains, mass retailers in Asia, e-commerce platforms, distributors, and (historically) the Australian "daigou" and cross-border e-commerce channels into China.
Customer types and end-markets
| Customer / channel | Markets | Notes from filings |
|---|---|---|
| Independent health food stores | Australia | Core Herbs of Gold heritage channel; health food and pharmacy channels together grew 18% in FY2025 |
| Pharmacy (independent, banner groups, chains) | Australia, Malaysia, Singapore, Vietnam | Primary growth driver in Australia in H1 2026 (Australia revenue +14%) |
| Retail chains / mass retailers | Malaysia, Singapore, Vietnam | VitaHealth's distribution backbone in Malaysia/Singapore; ConCung (Vietnam mother-and-baby chain) |
| E-commerce (domestic and cross-border) | China, Vietnam, Malaysia | Single China e-commerce partner appointed in 2019; transitioned to a new partner in 2025; new e-commerce distribution arrangement from September 2026 |
| Daigou (Australian-based resellers to Chinese consumers) | Australia → China | Deliberately reduced in FY2025 to support the in-market China strategy |
| Distributors | Vietnam, Indonesia, Thailand, export markets | New exclusive Herbs of Gold distributor appointed in Vietnam (2025) |
End-markets served are consumer health and wellness: general wellbeing, immunity, stress/sleep, women's and children's health, joint and bone health, beauty-from-within, and condition-specific herbal support. No single customer exceeded 10% of revenue in FY2025 or FY2024; in FY2023, one customer (reported in the Australia segment and widely understood to be the China cross-border partner) contributed A$12.4m, or 16.9% of revenue.
Independent characterisation
VLS is best understood as a two-engine regional brand house with an option on Asia. Engine one is VitaHealth in Malaysia and Singapore, a 50-plus-year-old consumer brand with deep retail relationships that has re-accelerated sharply (segment revenue +35% and EBIT +62% in FY2025) and now generates more than half of group EBIT before corporate costs. Engine two is Herbs of Gold in Australia, a practitioner-credible herbal brand that is broadening from health food stores into pharmacy, at the cost of higher marketing and staff spend (segment EBIT margin fell from 15.4% to 12.2% in FY2025 before recovering to 14.8% in H1 2026). The "option" — China and Vietnam — has been volatile and is currently loss-making at the EBIT line in H1 2026. Financially, the company is unusually conservative: zero bank debt since listing, cash equal to ~60% of equity, near-zero goodwill/intangibles, and a capital-return policy (dividends plus buy-backs) that has returned more than 100% of statutory net profit in FY2025 when buy-backs are included. The principal analytical tension is between this exemplary balance-sheet discipline and the absence of scale, liquidity and disclosure depth expected of larger listed consumer-health peers.
Strategy
Stated strategy — themes from the FY2025 Annual Report
Structural trend alignment: the Chairman frames VLS as positioned within the global shift toward "health, nutrition and longevity", citing preventive health, Asia's "wellness renaissance", the "longevity economy" from ageing populations, and self-directed health management.
Measured, sustainable expansion: growth "not for its own sake" but built on trusted products, relationships and local understanding; "thoughtful expansion in our chosen markets and a long-term perspective on value creation".
Trust and product integrity: brands that are effective, responsibly manufactured, scientifically grounded and transparently marketed.
Financial discipline: debt-free since listing; 16 consecutive years of rising dividends.
Operational strategy (MD Review): strengthen brands, expand distribution reach, develop innovative products aligned with consumer health trends; invest in brand development, product innovation and channel expansion.
Board guidance on near-term trade-off: continue increasing advertising and promotion and broadening distribution "within and beyond key markets", which "may impact profitability in the short term, with a view to increase profitability in the medium term".
Strategic initiatives — last 24 months
| Initiative | Timing | Detail and status |
|---|---|---|
| Australian pharmacy channel expansion | 2024–2026 | Expanded pharmacy offering; Health Food + Pharmacy +18% (FY2025); Australia +14% in H1 2026 driven by pharmacy |
| Daigou de-emphasis | FY2025 | Deliberately lower Australian daigou contribution to support in-market China strategy (mirrors H&H Group's mid-2025 decision to deprioritise corporate daigou) |
| China channel reset | 2025–2026 | Transition to a new trade partner (2025, slower than expected); new e-commerce distribution arrangement with a strategic partner from September 2026 to improve execution and brand representation |
| Vietnam channel build-out | 2024–2026 | Herbs of Gold across ConCung stores (2024); new exclusive Herbs of Gold distributor for pharmacy and e-commerce (2025); Vietnam +59% in H1 2026 |
| Malaysia/Singapore range expansion | 2024–2025 | New product pipeline and local marketing; segment +35% in FY2025 |
| Brand investment programme | Ongoing | Marketing spend up from A$5.4m (FY2023) to A$9.0m (FY2025) |
| Capital management | May 2025; renewed May 2026 | On-market buy-back of up to 15% of shares; 1,065,229 shares repurchased in FY2025 (A$2.24m); 1,123,996 in H1 2026 (A$1.16m); continuing in October 2026 |
| Dividend policy uplift | FY2025 | Payout raised to ~75% of NPAT (from 63% in FY2024); partial franking introduced as offshore profits increase |
| Employee ownership | June 2026 | 2.01m new LTIP shares issued |
| Climate disclosure readiness | From 1 Jan 2028 | Expects to be a Group 3 entity under AASB S2 |
No transformation programmes, formal cost-out targets, ESG targets or investor days have been announced.
Medium-term financial targets / guidance
The company does not publish medium-term targets. It issues short-horizon guidance near period-end (FY2025 guidance on 12 December 2025: sales A$91–92m, PBT A$13.2–13.7m — actual A$93.3m and A$14.4m, both above the range; H1 2026 guidance on 12 June 2026: sales A$46.3–47.3m, PBT A$6.8–7.3m — actual A$48.3m and A$8.1m, again above). For FY2026, the board stated in August 2026 that it will "provide further outlook in the fourth quarter". The only standing financial policy is the dividend payout ratio (~75% of NPAT in FY2025, "in line with Directors' dividend policy").
Products & Services
Disclosure limitation: VLS does not publish a product-level catalogue, SKU counts by brand, launch dates or pricing in its statutory filings. The group cites "circa 350 registered products" (FY2025 Annual Report) and "approximately 350+ registered products" (H1 2026 Presentation); older profiles cite over 400. Product-level revenue, pricing and specifications are therefore not publicly disclosed in filings. The catalogue below is organised by brand and segment using filing disclosures; individual SKUs are named only where they appear in company documents or verified trade press.
Herbs of Gold — VMS Operational (Australia); also Malaysia/Singapore, Vietnam, China
| Attribute | Detail |
|---|---|
| Description | Australian herbal and nutritional supplement brand founded 1989; acquired by VLS in 2001. Positioned on integrity, efficacy and practitioner credibility ("clean, effective and functional" formulations by naturopaths and pharmacists) |
| Categories (trade press / company commentary) | Stress and sleep (highlighted by NutraIngredients, August 2025), herbal medicines, minerals, superfoods, vitamins, children's health |
| Target customer | Health-conscious adults and families; health food store shoppers; increasingly pharmacy shoppers and healthcare professionals |
| Channels | Australian health food stores and pharmacies; ConCung (Vietnam mother-and-baby retail) and a new exclusive Vietnam pharmacy/e-commerce distributor (2025); China via cross-border e-commerce |
| Regulatory status | Australian listed complementary medicines (TGA) — specific ARTG numbers not reproduced in filings |
| Latest developments | Pharmacy-channel expansion in Australia (H1 2026 Australian revenue +14%); "targeted marketing initiatives and retailer partnerships continued to strengthen the Herbs of Gold brand" (H1 2026 Directors' Report) |
| Pricing model | Retail-price premium positioning; specific price points not disclosed |
| Named flagship SKUs | — |
VitaHealth — VMS Operational (Malaysia & Singapore); also Vietnam, Indonesia, Thailand, China
| Attribute | Detail |
|---|---|
| Description | Heritage brand: Vita Health began as a Singapore retail pharmacy in 1947 and launched its own VMS brand in 1973; acquired by VLS in 2000 together with the Malaysian and Singaporean businesses |
| Named flagship products (company) | Supa Formula Three; Crowning Glory (cited by the company as original flagship products) |
| Categories | Multivitamins, beauty/hair, general wellbeing, immunity and condition-specific supplements (portfolio breadth described as an "expanded product range" in FY2025) |
| Target customer | Mass-market and pharmacy shoppers in Malaysia and Singapore; mother-and-baby and pharmacy shoppers in Vietnam |
| Performance | Malaysia & Singapore segment record revenue A$44.8m (+35%) in FY2025, attributed to "increased consumer demand for VitaHealth branded products"; the company describes VitaHealth as strengthening its position as a leading regional supplement brand |
| Pricing model | — |
VitaScience — VMS Operational (Malaysia & Singapore)
| Attribute | Detail |
|---|---|
| Description | Third group brand, named in the FY2025 Chairman's Letter and third-party profiles; held through Vita Science Sdn Bhd (Malaysia) |
| Positioning | Science-led supplements (positioning inferred from brand name and entity; detailed range not disclosed) |
| Revenue contribution | — |
OTC medicines and health foods
The company states that its core business includes OTC medicines and health foods in addition to complementary medicines. Which brands carry OTC-registered products, and in which jurisdictions, is not publicly disclosed.
Services
No service offerings are disclosed.
Financial Narrative
Sources: FY2021 Prelim (FY2021 data); FY2022 Annual Report headline table and AR2023 growth rates (FY2022 data; FY2022 gross profit from Stock Analysis aggregator); FY2024 Prelim (FY2023 data as restated); FY2025 Annual Report (FY2024–FY2025). FY2023 revenue was originally reported at ~A$74.2m (AR2023 "up 10.9%") and is shown here as restated to A$73.43m in the FY2024 accounts. Discrepancy flagged.
Income statement
Notes: FY2021 and FY2022 EPS from InvestSMART (secondary). FY2024 basic EPS shown as originally reported (15.97c); FY2025 accounts present FY2024 comparative as 15.79c — discrepancy flagged. FY2022 PBT derived from the FY2023 Annual Report's "+16.0%" PBT growth and corroborated by InvestSMART (A$10.74m).
Margins
Revenue CAGR: FY2021–FY2025 (4 years): 13.0% p.a. FY2020–FY2025 (5 years, FY2020 revenue A$46.48m): 15.0% p.a. NPAT CAGR FY2020–FY2025 (FY2020 A$5.86m): 12.2% p.a.
Half-year comparison
Trailing twelve months to 30 June 2026 (analyst calculation): revenue A$96.0m; EBIT A$15.1m; PBT A$15.7m; NPAT A$11.1m; basic EPS 20.2 cents.
Balance sheet
Notes: FY2024 total assets/equity shown per FY2025 comparatives (A$71.89m / A$52.28m); the FY2024 Preliminary Report originally showed A$71.88m / A$52.28m — immaterial discrepancy. At 30 June 2026: total assets A$80.47m, cash A$33.70m, equity A$55.71m, inventories A$14.53m, lease liabilities A$2.16m, NTA per share A$0.92.
Cash flow
Note: The FY2025 Preliminary Report states operating cash flow before interest and tax of A$18.4m, whereas the FY2025 Annual Report's MD Review states A$18.8m — discrepancy flagged. H1 2026 statutory OCF was A$4.95m (H1 2025: A$6.60m), depressed by income tax paid of A$2.95m (A$1.14m); H1 2026 dividends paid A$5.17m and buy-backs A$1.16m.
Ratios
All ratios are analyst calculations from the reported statements; negative net debt denotes net cash. Interest coverage is not economically meaningful given trivial interest expense (lease interest).
Commentary on trends, inflections and drivers
Revenue. Growth has been continuous since at least FY2017, with FY2021 (+23%) benefiting from pandemic-era health demand and FY2025 (+17%) driven almost entirely by Malaysia & Singapore (+A$11.6m of the A$13.8m group increase). FY2023–FY2024 represented a deceleration to high-single-digit growth as China cross-border volumes fell away (single customer worth A$12.4m in FY2023 dropped below the 10% threshold in FY2024). H1 2026 growth slowed to 6.1% as China & Vietnam revenue fell 39%, masking 14% growth in Australia.
Gross margin. The trough at 57.7% in FY2023 reflected channel mix (lower-margin export/e-commerce sales into China) and input-cost inflation; recovery to 61.2% in FY2025 and 63.5% in H1 2026 reflects improved product mix in Australia and Malaysia/Singapore and the shrinking share of China exports. This is the single most important earnings driver of the last 18 months.
Operating leverage. EBIT margin compressed from 19.5% (FY2021) to ~15% (FY2024–FY2025) despite gross-margin recovery, because management deliberately stepped up marketing (from 7.3% to 9.6% of revenue between FY2023 and FY2025) and headcount (wages +A$3.1m in FY2025, +20%). The board explicitly flags that ongoing investment in advertising and channel expansion "may impact profitability in the short term". H1 2026 shows the first inflection: administrative costs grew only 2.5% against 6.1% revenue growth, lifting EBIT margin to 15.9%.
Profitability. NPAT rose from A$5.9m (FY2020) to A$10.4m (FY2025). FY2025's effective tax rate (27.7%) included A$1.22m of non-deductible expenditure offset by A$1.34m of newly recognised deferred tax assets. The group carries SGD15.8m (A$18.4m) of unrecognised Singapore tax losses — a latent asset worth up to ~A$3.1m at Singapore's 17% rate if Singapore profitability becomes sustainable.
Balance sheet. The group is debt-free with a cash pile that has grown from A$15.7m (end-FY2022) to A$35.6m (end-FY2025) despite rising cash returns. Goodwill and intangibles are negligible (acquired brands are carried at nil/historical cost), so reported ROE materially understates nothing and NTA approximates book value. Lease liabilities jumped to A$2.4m in FY2025 following a new five-year Herbs of Gold office lease effective May 2025.
Cash conversion. Working capital is the swing factor: FY2024 OCF collapsed to A$6.2m as inventories rose A$5.4m (raw materials +A$3.2m), then recovered to A$16.4m in FY2025 as inventories fell A$1.5m and other liabilities rose A$2.3m. Days inventory outstanding of 130–190 days is structurally high (long-dated imported raw materials, multi-market registrations, return rights) and is the main source of cash-flow volatility.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Sub-segment | Contents | Characterisation (company) |
|---|---|---|---|
VMS Operational | Australia | Herbs of Gold (and VitaHealth where sold) in the Australian domestic market — health food, pharmacy and daigou channels | Established brands/markets with high brand recognition and mature operations |
VMS Operational | Malaysia & Singapore | VitaHealth, Herbs of Gold and VitaScience in Malaysia and Singapore; exports into other Asian markets | Established |
VMS Investments | China & Vietnam | Exports/e-commerce into China (including direct exports formerly booked in Australia); Herbs of Gold and VitaHealth in Vietnam | Relatively new markets with low brand recognition, requiring ongoing group-funded investment |
Others | — | Indonesia, Thailand (49%/74%-owned entities) and other minor markets | Small, loss-making |
Corporate | — | Head-office costs, interest income on group cash | Cost centre |
Segment revenue (AUD Mn)
| Segment revenue (AUD Mn) | FY2024 | FY2025 |
|---|---|---|
Australia | 37.34 | 40.53 |
Malaysia & Singapore | 33.23 | 44.81 |
China & Vietnam | 8.94 | 7.93 |
Total group | 79.51 | 93.27 |
Segment EBIT (AUD Mn)
| Segment EBIT (AUD Mn) | FY2024 | FY2025 |
|---|---|---|
Australia | 5.74 | 4.93 |
Malaysia & Singapore | 5.91 | 9.60 |
China & Vietnam | 1.44 | 0.39 |
Others | -0.08 | -0.06 |
Corporate | -1.21 | -1.06 |
Group EBIT | 11.81 | 13.79 |
Segment EBIT margin (%)
| Segment EBIT margin (%) | FY2024 | FY2025 |
|---|---|---|
Australia | 15.4 | 12.2 |
Malaysia & Singapore | 17.8 | 21.4 |
China & Vietnam | 16.2 | 4.9 |
Group | 14.9 | 14.8 |
Segment share of revenue (%)
| Segment share of revenue (%) | FY2024 | FY2025 |
|---|---|---|
Australia | 47.0 | 43.5 |
Malaysia & Singapore | 41.8 | 48.0 |
China & Vietnam | 11.2 | 8.5 |
Segment revenue growth YoY (%) | FY2025 | — |
Australia | 8.6 | — |
Malaysia & Singapore | 34.8 | — |
China & Vietnam | -11.3 | — |
Group | 17.3 | — |
Segment revenue, old basis (AUD Mn)
| Segment revenue, old basis (AUD Mn) | FY2023 | FY2024 |
|---|---|---|
Australia (incl. China direct exports) | 42.76 | 44.44 |
Singapore | 6.25 | 7.57 |
Malaysia | 22.83 | 25.66 |
Others (Vietnam, Indonesia, Thailand) | 1.59 | 1.83 |
Total | 73.43 | 79.51 |
Segment EBIT, old basis (AUD Mn)
| Segment EBIT, old basis (AUD Mn) | FY2023 | FY2024 |
|---|---|---|
Australia | 6.24 | 6.70 |
Singapore | -0.01 | -0.35 |
Malaysia | 5.74 | 6.26 |
Others | 0.17 | -0.45 |
Corporate | -0.10 | -0.35 |
Segment revenue (AUD Mn) (Half-Yearly)
| Segment revenue (AUD Mn) | H1 2025 | H1 2026 |
|---|---|---|
Australia | 19.58 | 22.40 |
Malaysia & Singapore | 21.91 | 23.44 |
China & Vietnam | 4.05 | 2.47 |
Total | 45.54 | 48.31 |
Segment EBIT (AUD Mn) (Half-Yearly)
| Segment EBIT (AUD Mn) | H1 2025 | H1 2026 |
|---|---|---|
Australia | 2.17 | 3.31 |
Malaysia & Singapore | 4.89 | 5.38 |
China & Vietnam | -0.14 | -0.25 |
Others | -0.02 | -0.04 |
Corporate | -0.48 | -0.73 |
Group EBIT | 6.41 | 7.67 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 57.10 | 66.89 | 73.43 | 79.51 | 93.27 |
Revenue growth (%) | 22.9 | 17.1 | 9.8 | 8.3 | 17.3 |
Gross profit (AUD Mn) | 34.81 | 39.74 | 42.38 | 47.24 | 57.04 |
EBITDA, company-defined (AUD Mn) | — | — | 12.54 | 12.42 | 14.80 |
EBIT, profit from continuing operations before interest and tax (AUD Mn) | 11.16 | — | 12.03 | 11.81 | 13.79 |
Profit before tax (AUD Mn) | 11.20 | 10.74 | 12.45 | 12.64 | 14.43 |
Net profit after tax (AUD Mn) | 8.25 | 7.34 | 9.08 | 8.78 | 10.43 |
EPS basic (A cents) | 15.6 | 13.1 | 16.92 | 15.97 | 18.63 |
EPS diluted (A cents) | — | — | 16.60 | 15.97 | 18.35 |
Dividends per share declared (A cents) | 5.75 | 6.00 | 9.00 | 10.00 | 14.00 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 61.0 | 59.4 | 57.7 | 59.4 | 61.2 |
EBITDA margin (%) | — | — | 17.1 | 15.6 | 15.9 |
EBIT margin (%) | 19.5 | — | 16.4 | 14.9 | 14.8 |
PBT margin (%) | 19.6 | 16.1 | 17.0 | 15.9 | 15.5 |
Net margin (%) | 14.4 | 11.0 | 12.4 | 11.0 | 11.2 |
Effective tax rate (%) | 26.4 | 31.6 | 27.1 | 30.6 | 27.7 |
Income Statement
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Distribution expenses (AUD Mn) | 5.27 | 6.59 | 8.22 |
Marketing expenses (AUD Mn) | 5.37 | 7.31 | 8.98 |
Administrative expenses (AUD Mn) | 18.70 | 20.29 | 24.09 |
of which wages, salaries and employee costs (AUD Mn) | 14.00 | 15.08 | 18.15 |
Occupancy expenses (AUD Mn) | 0.83 | 1.01 | 1.08 |
Product registration costs (AUD Mn) | 0.34 | 0.40 | 0.59 |
Marketing as % of revenue | 7.3 | 9.2 | 9.6 |
Distribution as % of revenue | 7.2 | 8.3 | 8.8 |
Administrative as % of revenue | 25.5 | 25.5 | 25.8 |
Income Statement and Margin Analysis (%) (Half-Yearly)
| Metric | H1 2025 | H1 2026 |
|---|---|---|
Revenue (AUD Mn) | 45.54 | 48.31 |
Gross profit (AUD Mn) | 27.39 | 30.68 |
Gross margin (%) | 60.1 | 63.5 |
Marketing expenses (AUD Mn) | 4.48 | 5.04 |
Distribution expenses (AUD Mn) | 3.97 | 4.78 |
Administrative expenses (AUD Mn) | 11.61 | 11.90 |
EBIT (AUD Mn) | 6.41 | 7.67 |
PBT (AUD Mn) | 6.78 | 8.08 |
NPAT (AUD Mn) | 4.82 | 5.54 |
EPS basic (A cents) | 8.61 | 10.22 |
EPS diluted (A cents) | 8.61 | 10.04 |
Interim DPS (A cents) | 4.5 | 5.0 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (AUD Mn) | — | — | 59.81 | 71.89 | 82.36 |
Cash and equivalents (AUD Mn) | — | 15.69 | 24.63 | 28.60 | 35.56 |
Bank borrowings (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Lease liabilities, current (AUD Mn) | — | — | 0.21 | 0.30 | 0.48 |
Lease liabilities, non-current (AUD Mn) | — | — | 0.18 | 0.21 | 1.91 |
Net debt incl. leases (AUD Mn) | — | — | -24.24 | -28.08 | -33.17 |
Total equity (AUD Mn) | — | 36.50 | 43.33 | 52.28 | 56.16 |
Goodwill and intangibles (AUD Mn) | — | — | 0.03 | 0.05 | 0.04 |
Inventories (AUD Mn) | — | — | 11.15 | 16.60 | 15.08 |
Trade and other receivables (AUD Mn) | — | — | 11.22 | 12.00 | 13.64 |
Working capital, current assets less current liabilities (AUD Mn) | — | — | 32.07 | 39.62 | 41.68 |
Net tangible assets per share (AUD) | — | — | 0.73 | 0.88 | 0.94 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net operating cash flow, statutory (AUD Mn) | — | — | 12.98 | 6.16 | 16.43 |
Operating cash flow before interest and tax, company measure (AUD Mn) | 8.73 | 6.97 | 15.90 | 6.20 | 18.40 |
Capex, purchase of PP&E (AUD Mn) | — | — | 0.66 | 0.20 | 0.57 |
Lease principal payments (AUD Mn) | — | — | 0.17 | 0.29 | 0.77 |
Free cash flow, OCF less capex less lease payments (AUD Mn) | — | — | 12.15 | 5.67 | 15.09 |
Dividends paid (AUD Mn) | — | — | 3.37 | 5.17 | 6.08 |
Share buy-backs (AUD Mn) | — | — | 0.21 | 1.39 | 2.24 |
LTIP loan repayments received (AUD Mn) | — | — | 0.87 | 3.86 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
ROE, NPAT / average equity (%) | 22.7 | 18.4 | 19.2 |
ROA, NPAT / closing total assets (%) | 15.2 | 12.2 | 12.7 |
ROIC, NOPAT / (equity + leases − cash) (%) | 46.0 | 33.7 | 43.2 |
Current ratio (x) | 2.98 | 3.06 | 2.72 |
Debt to equity, bank debt (x) | 0 | 0 | 0 |
Debt to equity, incl. leases (x) | 0.01 | 0.01 | 0.04 |
Net debt / EBITDA (x) | -1.93 | -2.26 | -2.24 |
Interest coverage, EBIT / interest expense (x) | 200 | 257 | 121 |
Asset turnover, revenue / closing assets (x) | 1.23 | 1.11 | 1.13 |
Days sales outstanding (days) | 53 | 54 | 52 |
Days inventory outstanding (days) | 131 | 188 | 152 |
Days payables outstanding (days) | 66 | 63 | 68 |
Cash conversion cycle (days) | 119 | 179 | 136 |
Dividend payout ratio, declared DPS / EPS (%) | 53 | 63 | 75 |
Region revenue (AUD Mn)
| Region revenue (AUD Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Malaysia | 22.83 | 25.66 | — |
Singapore | 6.25 | 7.57 | — |
Malaysia and Singapore combined | 29.08 | 33.23 | 44.81 |
Australia, old basis incl. China direct exports | 42.76 | 44.44 | — |
Australia, new basis domestic | — | 37.34 | 40.53 |
China and Vietnam, new basis | — | 8.94 | 7.93 |
Other Asia (Vietnam, Indonesia, Thailand), old basis | 1.59 | 1.83 | — |
Region growth (%)
| Region growth (%) | FY2024 | FY2025 |
|---|---|---|
Malaysia | 12.4 | — |
Singapore | 21.1 | — |
Malaysia and Singapore combined | 14.3 | 34.8 |
Australia, old basis | 3.9 | — |
Australia, new basis | — | 8.6 |
China and Vietnam | — | -11.3 |
Region share of revenue (%)
| Region share of revenue (%) | H1 2025 | H1 2026 |
|---|---|---|
Australia | 43.0 | 46.4 |
Malaysia and Singapore | 48.1 | 48.5 |
China and Vietnam | 8.9 | 5.1 |
Share Price & Returns
| Reference date | Share price (AUD) | Source |
|---|---|---|
30 Jun 2023 | 1.56 | Market Index |
27 May 2025 | 1.87 | Simply Wall St |
Start of 2026 (derived) | ~2.58 | Derived from MarketScreener YTD +7.36% at A$2.77 |
16 Apr 2026 | 2.49 | Motley Fool |
12 Jun 2026 | 2.43 | InvestSMART |
5 Oct 2026 | 2.77 | MarketScreener |
13 Oct 2026 | 2.84 | Investing.com |
Valuation Multiples
| Multiple | VLS | Basis |
|---|---|---|
Market capitalisation | ~A$159m | — |
Enterprise value | ~A$127m | Market cap less A$33.7m cash plus A$2.2m leases (30 Jun 2026) |
P/E (trailing) | ~14.0x | TTM basic EPS 20.2 cents |
P/E (FY2025) | ~15.2x | FY2025 basic EPS 18.63 cents |
EV/EBITDA (trailing) | ~7.9x | TTM EBITDA ~A$16.1m (EBIT A$15.1m plus ~A$1.0m D&A) |
EV/Sales (trailing) | ~1.3x | TTM revenue A$96.0m |
P/B | ~2.9x | Equity A$55.7m |
Dividend yield (trailing) | ~5.1% | 9.5c final + 5.0c interim = 14.5c |
Dividend metric
| Dividend metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
Total DPS declared (A cents) | 4.25 | 5.75 | 6.00 | 9.00 | 10.00 | 14.00 |
Interim DPS (A cents) | — | 2.75 | — | 3.00 | 3.50 | 4.50 |
Final DPS (A cents) | — | 3.00 | — | 6.00 | 6.50 | 9.50 |
Franking of total dividend (%) | 100 | 100 | 100 | 100 | 100 | 64 |
Authorisation by Period
| Period | Authorisation | Shares repurchased | Cost (AUD Mn) |
|---|---|---|---|
FY2023 | Prior programme | 126,475 | 0.21 |
FY2024 | Prior programme | 714,555 | 1.39 |
FY2025 | Up to 15% (announced 22 May 2025) | 1,065,229 | 2.24 |
H1 2026 | Continuing / renewed May 2026 | 1,123,996 (incl. 658,502 unpaid LTIP shares cancelled) | 1.16 |
Jul–Oct 2026 | Renewed up to 15% | ~478,000 (cumulative to ~5 Oct 2026) | — |
“—” = not publicly disclosed.
Analyst Conclusions
Management guidance
No FY2026 full-year guidance has been issued. The board described itself as "pleased with the HY June 2026 results", noted looming economic uncertainty, and committed to provide further outlook in the fourth quarter of 2026 (historically mid-December). Structural commentary (FY2025 Annual Report) remains positive on health, nutrition and longevity demand across Australia and Asia.
Illustrative arithmetic (not guidance): H2 FY2025 delivered revenue of A$47.7m and PBT of A$7.7m. If H2 FY2026 grows at the H1 FY2026 rate (+6%), FY2026 revenue would be roughly A$99m; holding H2 PBT flat would imply FY2026 PBT of roughly A$15.7m (+9%). These are analyst scenarios only.
Consensus growth expectations
Not available — no published broker consensus.
Bull case
-
Margin structurally higher: gross margin has expanded ~580bps from FY2023 to H1 2026 (57.7% → 63.5%) on mix; with marketing investment now in the base and admin growth slowing, EBIT margin could trend back toward the high-teens achieved in FY2021 (19.5%).
-
Two compounding engines plus Vietnam: Australia (+14%) and Malaysia/Singapore (+7% on a record base) are both growing in H1 2026, while Vietnam (+59%) offers a third leg; China at only ~5% of revenue limits further downside and its reset offers upside.
-
Capital return and valuation support: ~5% trailing yield, active 15% buy-back authority, net cash equal to ~21% of market capitalisation, and an EV/EBITDA under 8x for a business earning ROE near 20% with no leverage.
Bear case
-
China and channel fragility: a third China channel configuration in seven years, with China & Vietnam revenue down 39% in H1 2026, suggests structural rather than cyclical weakness; repeated reliance on single partners creates concentration risk.
-
Malaysia/Singapore normalisation: growth decelerated from +35% (FY2025) to +7% (H1 2026); as the largest profit pool (A$9.6m EBIT), any reversal — competitive response, MYR weakness or retailer destocking — would hit group earnings disproportionately.
-
Liquidity, governance and dilution discount: six holders own ~67%, average daily volume is ~18,000 shares, the board is small and not majority-independent, and loan-funded LTIP issues (2.01m shares in June 2026, 7.3% of capital outstanding at year-end) dilute holders while partly offsetting buy-backs.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | What to watch |
|---|---|---|
| Q4 outlook / FY2026 guidance | ~December 2026 | Whether H2 growth holds at mid-single digits and PBT exceeds A$15m |
| FY2026 Preliminary Final Report | ~15 February 2027 | Gross margin sustainability above 62%; Australia EBIT margin; final dividend and franking level |
| China e-commerce partner performance | From September 2026 | Stabilisation of China & Vietnam segment revenue and return to EBIT breakeven |
| Vietnam scaling | Ongoing | Revenue trajectory and retailer ranging wins |
| Malaysia/Singapore growth rate | H2 2026 | Re-acceleration vs normalisation; MYR/SGD translation |
| Working capital | FY2026 | Inventory days vs 152 in FY2025; OCF conversion |
| Capital management | Ongoing | Buy-back pace; payout ratio; any special dividend from cash pile |
| Board renewal | 2027 AGM | Independent director additions; gender diversity |
| AASB S2 preparation | Toward 2028 | Climate disclosure readiness |
Concluding analyst verdict
Vita Life Sciences is a high-quality micro-cap consumer-health franchise whose financial discipline is better than its market profile suggests. Over five years it has compounded revenue at roughly 15% a year to a record A$93.3m, sustained gross margins above 60%, generated an ROE near 20% without a dollar of bank debt, and lifted its dividend from 4.25 cents to 14.0 cents while also buying back stock. The first half of FY2026 reinforced the pattern: guidance was beaten, gross margin expanded to 63.5%, and pre-tax profit grew 19% on 6% revenue growth — evidence that the heavy brand-investment phase of FY2024–FY2025 is beginning to yield operating leverage.
The investment debate centres on mix and sustainability rather than solvency. The group's profit pool has migrated decisively to VitaHealth in Malaysia and Singapore, which now earns more than half of segment EBIT; Australia has re-accelerated via pharmacy; and China, once a A$12m single-customer channel, has shrunk to a sub-scale, loss-making "investment" market undergoing yet another partner reset. Vietnam is promising but small. Against this, the valuation — roughly 14x trailing earnings, under 8x EV/EBITDA, a ~5% yield and net cash covering about a fifth of the market capitalisation — does not appear to price in heroic assumptions.
The discount that persists is largely structural: a tightly held register, thin trading, no broker coverage, limited segment and product disclosure, and a small board whose independence profile falls short of best practice. These factors are unlikely to change quickly and justify a liquidity discount relative to larger consumer-health peers. On balance, the evidence supports a constructive view on fundamentals with a "quality, but illiquid" caveat: the most important near-term signals are the December 2026 outlook statement, the durability of Malaysian/Singaporean growth, and whether the September 2026 China partnership can stabilise the investment segment. Absent a China recovery, the base case is steady high-single-digit earnings growth supported by margin mix and ongoing capital returns.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed / tenure | Qualifications | Prior / other roles |
|---|---|---|---|---|
Henry G Townsing | Non-Executive Chairman; Chair of Remuneration Committee; Audit Committee member | Director 1985–1992, 2004–2009, reappointed 22 Dec 2011; Acting Chairman from 13 Oct 2016; Chairman from 28 May 2021 | Dip Val | 30+ years in corporate finance and private equity; director of CVC Venture Managers Pty Ltd and Pilmora Pty Ltd; former director of Cyclopharm Ltd (MarketScreener). Resides Melbourne |
Andrew O'Keefe | Managing Director (executive) | MD since 1 Jan 2017; CEO Herbs of Gold Australia from Oct 2014 | GAICD, Dip. Mkt Mgt | 20+ years in Australian pharmaceutical and healthcare industry; previously CEO of Australia's largest health food distributor and retailer; Chairman of Complementary Medicines Australia (CMA website). Resides Sydney |
Peter Osborne | Independent Non-Executive Director; Audit Committee member | Since 1 Aug 2023 | B Sc, Pg Dip Mkt | Managing Director Asia, Blackmores Ltd (2009–2020); Australian Senior Trade Commissioner in Beijing, Shanghai, Hong Kong and Taipei; director ATP Science; advisor to Aurizon, Team Global Express, Edison Partners, Daiken Biomedical, Bain & Company, Blackstone; UTS Australia-China Relations Institute advisory board. Resides Taipei |
Jack Teoh | Non-Executive Director; Remuneration Committee member | Since 30 Sep 2022 | B Com | Businessman in finance and technology; NED of TPG Telecom since March 2021; former director of Tuas Ltd (Jul 2020–Aug 2022) and Total Forms Pty Ltd. Associated with the Teoh family, a ~15% shareholder (Vicky Teoh). Resides Sydney |
Executive Leadership Team
| Name | Title | Tenure | Qualifications / background |
|---|---|---|---|
Andrew O'Keefe | Managing Director | Since 1 Jan 2017 | As above |
Chin L Khoo | CFO and Company Secretary | CFO since 1 May 2017; Co Sec since 30 Jun 2017; previously with group 2004–2011 | CA, CPA, AGIA, MBA; 30+ years across Asia-Pacific industries |
K S Beh | Country Manager — Malaysia & Singapore | — | — |
Shaun Rutherford | CEO Australia | — | — |
Melissa Pereira | Group Marketing Manager | — | — |
“—” = not publicly disclosed.
Directors' Remuneration
| Person | Salary and fees | STI | LTIP (share-based) | Other long-term | Superannuation | Total FY2025 | Total FY2024 | Performance-related FY2025 (%) |
|---|---|---|---|---|---|---|---|---|
Henry Townsing (Chair) | 80,000 | 0 | 0 | 0 | 9,400 | 89,400 | 120,244 | — |
Andrew O'Keefe (MD) | 540,000 | 0 | 82,165 | 25,589 | 29,966 | 677,720 | 772,868 | 12.1 |
Jack Teoh (NED) | 48,000 | 0 | 0 | 0 | 5,660 | 53,660 | 44,500 | — |
Peter Osborne (NED) | 53,640 | 0 | 0 | 0 | 0 | 53,640 | 40,000 | — |
Chin L Khoo (CFO) | 213,068 | 10,000 | 34,235 | 4,377 | 26,133 | 287,813 | 323,790 | 15.4 |
K S Beh (Malaysia & Singapore) | 395,378 | 123,851 | 41,082 | 0 | 36,653 | 596,964 | 526,802 | 27.6 |
Shaun Rutherford (CEO Australia) | 320,400 | 24,974 | 41,082 | 7,032 | 29,966 | 423,454 | 532,054 | 15.6 |
Melissa Pereira (Marketing) | 146,229 | 9,500 | 20,541 | 3,277 | 18,274 | 197,821 | 197,253 | 15.2 |
Grand total | 1,796,715 | 168,325 | 219,105 | 40,275 | 156,052 | 2,380,472 | 2,557,511 | 16.3 |
Governance Overview
| Attribute | Assessment |
|---|---|
Board size | 4 (1 executive, 3 non-executive) |
Chair / CEO separation | Yes — Chairman (Townsing) separate from MD (O'Keefe) |
Independence (analyst view) | Osborne appears independent. Townsing's combined tenure (~25 years across three terms) and related-party arrangements (storage fees to Land Real Pty Ltd; prior consulting fees to Atlas Horizon Pty Ltd — both immaterial, ~A$1,000) challenge independence under ASX Principles. Teoh is associated with a substantial shareholder. A majority-independent board is therefore unlikely on a strict ASX Corporate Governance Council test |
Committees | Audit (Townsing, Osborne — 3 meetings, full attendance); Remuneration (Townsing chair, Teoh — 3 meetings); Nomination (no meetings held in FY2025) |
Board meetings FY2025 | 9 held; O'Keefe and Townsing 9/9; Teoh and Osborne 8/9 |
Gender diversity | 0 of 4 directors are women; 2 of 4 non-director KMP are women |
Major Shareholders
| Holder | Shares | % |
|---|---|---|
Chemical Overseas Limited | 8,551,439 | 15.4 |
Vicky Teoh | 8,435,693 | 15.2 |
Barings Acceptance Limited | 7,371,832 | 13.3 |
Anglo Australian Christian and Charitable Fund | 6,276,040 | 11.3 |
Tie Lim Sung (Eddie Tie, former MD) | 4,010,000 | 7.2 |
SG Hiscock & Company Limited | 2,870,584 | 5.1 |
Competitive Landscape
Key Competitors
| Competitor | Owner | Markets overlapping VLS | Relative positioning |
|---|---|---|---|
Swisse | H&H Group (HKEX: 1112) | Australia, China, Singapore/Malaysia | No.1 VMS brand in Australia and mainland China; Swisse revenue reached US$1bn in 2025 (H&H 2025 results) — >15x VLS group revenue |
Blackmores (incl. BioCeuticals) | Kirin Holdings (acquired 2023; delisted from ASX) | Australia, Malaysia, Singapore, China, Vietnam, Indonesia, Thailand | Market leader with roughly ten times VLS revenue (Sweetstocks); VLS director Osborne ran Blackmores Asia 2009–2020 |
Nature's Way | Pharmacare Laboratories | Australia | Mass-pharmacy and grocery VMS |
Cenovis / Ostelin | Opella (former Sanofi consumer health) | Australia, Asia | Mass-market VMS; strong pharmacy/grocery presence |
Thompson's and other practitioner brands | Integria Healthcare | Australia | Herbal/practitioner overlap with Herbs of Gold |
Metagenics | Private | Australia | Practitioner-only channel |
Bio Concepts | Private | Australia | Practitioner-only herbal |
Fusion Health | Private | Australia | Herbal/naturopathic, health food and pharmacy |
Kordel's | Cambert (private) | Singapore, Malaysia | Direct regional competitor to VitaHealth |
Appeton | Kotra Pharma (Bursa Malaysia) | Malaysia, ASEAN | Local Malaysian brand (nutrition/supplements) |
Holistic Way, BiO-LiFE and other local brands | Various | Malaysia, Singapore | Local pharmacy competitors |
Amway Nutrilite, Herbalife, Shaklee | Multinationals | Malaysia, Vietnam, China | Direct-selling competitors |
By-Health | Shenzhen-listed | China | Domestic Chinese VMS leader |
Peer Comparison FY2025
| Metric | Vita Life Sciences (FY2025) | H&H Group (FY2025) | Blackmores |
|---|---|---|---|
Revenue | A$93.3m | RMB 14,353.6m (+10.0%); Swisse ~US$1bn | No longer reports publicly (Kirin subsidiary); ~10x VLS on last public data (Sweetstocks) |
Revenue growth | +17.3% | +10.0% (reported), +10.3% like-for-like | — |
Profitability | EBIT margin 14.8%; EBITDA margin 15.9%; net margin 11.2% | Adjusted comparable EBITDA margin 14.3%; attributable net profit RMB 196m (~1.4% net margin) | — |
Gross margin | 61.2% | — | — |
R&D intensity | Not disclosed (registration costs 0.6% of revenue) | — | — |
Balance sheet | Net cash A$33.2m, no bank debt | Cash >RMB 1.7bn; deleveraging | — |
“—” = not publicly disclosed.
